

> Goal: characterize risk of Pt & procedure → appropriate testing (ie, results will ∆ management) and interventions (ie, reasonable probability of ↓ risk of MACE)


# CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY

_Goal: characterize risk of Pt & procedure_ → _appropriate testing (ie, results will_ ∆ _management) and interventions (ie, reasonable probability of_ ↓ _risk of MACE)_

### Preoperative evaluation (_NEJM_ 2015;373:2258)

### Figure 1-7 Approach to preop CV eval for non-CV surgery (modified from _Circ_ 2014;130:e278)

![](images/00034.jpeg)

<table><colgroup><col> <col> <col></colgroup><tbody><tr><td colspan="3"><p><b>Noninvasive Testing Result</b></p></td></tr><tr><td><p><b>High Risk</b></p></td><td><p><b>Intermediate Risk</b></p></td><td><p><b>Low Risk</b></p></td></tr><tr><td><p><b><i>Ischemia at</i></b> &lt;<b><i>4 METs</i></b> <i>manifested</i> by ≥1 <i>of:</i></p><p><span>•</span> Horiz/down ST ↓ ≥1 mm or STE</p><p><span>•</span> ≥5 異常 leads or ischemic ECG ∆s lasting &gt;3 min after exertion</p><p><span>•</span> SBP ↓ 10 mmHg or typical angina</p></td><td><p><b><i>Ischemia at</i> 4–6 <i>METs</i></b></p><p><i>manifested by</i> ≥1 <i>of:</i></p><p><span>•</span> Horiz/down ST ↓ ≥1 mm</p><p><span>•</span> 3–4 異常 leads</p><p><span>•</span> 1–3 min after exertion</p></td><td><p><b><i>No ischemia or</i></b></p><p><b><i>at</i></b> &gt;<b>7 METs with</b></p><p><span>•</span> ST ↓ ≥1 mm or</p><p><span>•</span> 1–2 異常 leads</p></td></tr></tbody></table>

### Additional preoperative testing (_Circ_ 2014;130:e278)

• ECG if known cardiac disease and possibly reasonable in all, except if low-risk surgery

• TTE if any of following & prior TTE >12 mo ago or prior to ∆ in sx: dyspnea of unknown origin; hx of HF with ↑ dyspnea; suspect (eg, murmur) or known ≥ moderate valvular dis.

### Coronary artery disease

• If possible, wait ~60 d after MI in the absence of revascularization before elective surgery

• Coronary revasc guided by standard indications. Has not been shown to ∆ risk of death or postop MI when done prior to elective vasc. surgery (_NEJM_ 2004;351:2795).

### Heart failure (_JACC_ 2014;64:e77)

• Decompensated HF should be optimally Rx’d prior to elective surgery

• 30-d CV event rate: symptomatic HF > asx HFrEF > asx HFpEF > no HF

### Valvular heart disease

• If meet criteria for valve intervention, do so before elective surgery (postpone if necessary)

• If severe valve disease and surgery urgent, intra- & postoperative hemodynamic monitoring reasonable (espec for AS, because at ↑ risk even if sx not severe; be careful to maintain preload, avoid hypotension, and watch for atrial fibrillation)

### Cardiac implantable electronic devices

• Discuss with surgical team need for device (eg, complete heart block) & consequences if interference with fxn, and likelihood of electromagnetic interference

• Consider reprogramming, magnet use, etc. as needed

### Pre- & perioperative pharmacologic management

• **ASA:** continue in 病人 with existing indication. Initiation prior to surgery does not ↓ 30-d ischemic events and ↑ bleeding (_NEJM_ 2014;370:1494), but 病人 with recent stents excluded.

• **Dual antiplatelet therapy:** delay elective surg 14 d after balloon angioplasty, 30 d after BMS and ideally 6 mo (min 3 mo) after DES (_JACC_ 2016; 68:1082) unless risk of bleeding > risk of stent thrombosis or ACS. If must discontinue P2Y12 inh, continue ASA and restart P2Y12 inh as soon as possible; can consider IV cangrelor if high-risk (_JAMA_ 2012;307:265).

• **β-blockers** (_JAMA_ 2015;313:2486)

Continue βB in 病人 on them chronically. Do not stop βB abruptly postop (may cause reflex sympathetic activation). Use IV if Pt unable to take PO.

Reasonable to initiate if intermed- or high-risk ⊕ stress test, or RCRI ≥3, espec if vasc surgery. Initiate ≥1 wk prior to surgery (_not day of_), use low-dose, short-acting βB, and titrate to achieve HR and BP goal (? HR ~55–65). Avoid bradycardia and HoTN.

• **Statins:** ↓ ischemia & CV events in 病人 undergoing vascular surg (_NEJM_ 2009;361:980). Consider if risk factors & non–low-risk surgery and in all 病人 undergoing vascular surgery.

• ACEI/ARB: holding 24 h preop to ↓ intraop HoTN (_Anes_ 2017;126:16). Restart as soon as possible.

• Amiodarone: ↓ incidence of postop AF if started prior to surgery (_NEJM_ 1997;337:1785)

### Postoperative monitoring

• ECG if known CAD or high-risk surgery. Consider if >1 risk factor for CAD.

• Routine troponin prognostic (_JAMA_ 2017;317:1642) but ✔ only if sx/ECG ∆s suggestive of ACS
